olmesartan has been researched along with Bright Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asakura, K; Komatsuda, A; Kuroki, J; Maki, N; Nishinari, T; Okuyama, S; Sawada, K; Wakui, H | 1 |
| Chen, R; Eisner, C; Hu, X; Huang, Y; Kopp, JB; Leelahavanichkul, A; Mizel, D; Schnermann, J; Star, RA; Wright, EC; Yan, Q; Yuen, PS; Zhou, H | 1 |
1 review(s) available for olmesartan and Bright Disease
| Article | Year |
|---|---|
Successful treatment of post-MRSA infection glomerulonephritis with steroid therapy.
Topics: Angiotensin II Type 1 Receptor Blockers; Anti-Bacterial Agents; Biopsy; Drug Therapy, Combination; Glomerulonephritis; Humans; Imidazoles; Male; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Prednisolone; Staphylococcal Infections; Tetrazoles | 2008 |
1 other study(ies) available for olmesartan and Bright Disease
| Article | Year |
|---|---|
Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model.
Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chronic Disease; Desoxycorticosterone; Disease Models, Animal; Disease Progression; Fibrosis; Genetic Predisposition to Disease; Glomerulonephritis; Heart Diseases; Hydralazine; Hypertension; Imidazoles; Infusion Pumps, Implantable; Infusions, Subcutaneous; Kidney; Kidney Diseases; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Nephrectomy; Sodium Chloride, Dietary; Species Specificity; Telemetry; Tetrazoles; Time Factors; X-Ray Microtomography | 2010 |